中药联合索拉非尼治疗中晚期原发性肝癌的疗效评价

Efifcacy evaluation of traditional Chinese medicine combined with sorafenib in the treatment of primary ;hepatocellular carcinoma in the middle and late stage

目的：评价单纯索拉非尼治疗与中药联合索拉非尼治疗中晚期原发性肝癌患者的疗效。方法选择2010年1月至2015年12月沈阳军区总医院收治的中晚期原发性肝癌患者48例，将其随机分为单纯索拉非尼治疗和中药联合索拉非尼治疗两组，各24例。对比分析其多层螺旋CT影像改变及肝功能变化。结果两个月后多层螺旋CT检查结果显示：两组在肿瘤大小、肿瘤数目、肝外转移例数及门静脉癌栓例数方面差异均无统计学意义（均P〉0.05），两种方法对抑制中晚期肝癌肿瘤生长与转移疗效无明显差异。而在肝功能方面，中药联合索拉非尼治疗组的总胆红素（TBIL）、直接胆红素（DBIL）、丙氨酸氨基转移酶（ALT）、白蛋白（ALB）和球蛋白（GLB）等指标，其改善情况明显优于单纯索拉非尼治疗组，差异有统计学意义（P〈0.05）。结论与单纯化疗相比，中药联合治疗中晚期肝癌对肿瘤生长与转移无明显效果，但是对提升患者肝功能及患者生存质量有一定效果。

Objective Evaluation of the treatment effects between sorafenib soley and by combination of SLFN and Chinese Medicine on mid to later phase hepatic carcinomas patients. Methods Take 48 mid to later phase hepatic carcinomas patients of our hospital from 2010 to 2015. Randomly assign 24 patients to sorafenib group and 24 to sorafenib combine Chinese medicine group. To compare the change of their liver function and multilayer spiral MSCT image. Results There were no significant statistical difference between the two groups on size of the tumors, liver diffusion outside, cancer embolus of portal vein（P〉0.05）. But there were meaningful statistical difference on TBIL, DBIL, ALT, ALB and GLB（P〈0.05）. Conclusions Compare to chemotherapy only method, there are no different results on tumor growth and diffusion by combing with Chinese Medicine with sorafenib, but there are some effect on improving liver function and life quality.